Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens-Reference-Cited by-同舟云学术

Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens

Published:2021-06-14 Issue: Volume: Page:1-10
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zamagni Elena¹²,Dhanasiri Sujith³,Ghale Arun⁴,Moore Adam⁴,Roussel Murielle⁵^ORCID

Affiliation:

1. IRCCS University Hospital of Bologna, Seràgnoli Institute of Hematology, Bologna, Italy

2. Department of Specialized, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy

3. Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

4. Adelphi Real World, Bollington, UK

5. Department of Clinical Hematology and Cell Therapy, University Hospital, Limoges, France

Funder

Bristol Myers Squibb

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1924369

Reference21 articles.

1. Cancer statistics, 2020

2. Multiple myeloma

3. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

4. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

5. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries;European Journal of Cancer;2024-04

2. More intensive therapy has a better effect for frail parents with multiple myeloma;Blood Advances;2023-10-13

3. Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia;Cancers;2023-08-18

4. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study;Cancers;2023-08-09

5. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States;BMC Cancer;2022-08-18